Paediatric pneumococcal disease in Central Europe
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- dítě MeSH
- imunizace MeSH
- incidence MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- otitis media epidemiologie imunologie mikrobiologie prevence a kontrola MeSH
- pneumokoková meningitida epidemiologie imunologie mikrobiologie prevence a kontrola MeSH
- pneumokokové vakcíny aplikace a dávkování MeSH
- pneumonie pneumokoková epidemiologie imunologie mikrobiologie prevence a kontrola MeSH
- předškolní dítě MeSH
- sepse epidemiologie imunologie mikrobiologie prevence a kontrola MeSH
- sérotypizace MeSH
- Streptococcus pneumoniae * klasifikace imunologie MeSH
- vakcíny konjugované aplikace a dávkování MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- pneumokokové vakcíny MeSH
- vakcíny konjugované MeSH
Streptococcus pneumoniae causes considerable global paediatric morbidity and mortality, despite the availability of safe and effective pneumococcal conjugate vaccines (PCVs). To justify the introduction of PCVs, accurate information on the burden of disease is required. Here, we present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. The data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21-22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database using the search terms 'pneumococcal' or 'Streptococcus pneumoniae', in combination with 'otitis media', 'pneumonia', 'meningitis' or 'bacteraemia/sepsis', and '[Central European country name]'. The incidence of pneumococcal disease appears to be lower in Central Europe than previously reported for Europe as a whole, with the highest risk in infants aged 0-2 years. The fatality rates in the under fives from invasive infections are up to 40%. A paucity of comprehensive country-specific data on pneumococcal disease burden arises from the lack of homogenous surveillance programmes. Standardised, active surveillance systems are required for the accurate evaluation of the pneumococcal disease burden in the region. Only then can the need for vaccination be addressed.
Zobrazit více v PubMed
J Med Microbiol. 2010 Sep;59(Pt 9):1079-1083 PubMed
Med Sci Monit. 2008 Dec;14(12):PH59-64 PubMed
Curr Opin Infect Dis. 2003 Jun;16(3):271-7 PubMed
Euro Surveill. 2009 May 07;14(18):pii/19202; author reply pii/19200 PubMed
Vaccine. 2010 Sep 7;28(39):6406-7 PubMed
Ann Otol Rhinol Laryngol Suppl. 1980 May-Jun;89(3 Pt 2):351-6 PubMed
J Antimicrob Chemother. 2002 Sep;50 Suppl S1:61-70 PubMed
Int J Infect Dis. 2010 Mar;14(3):e197-209 PubMed
Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):780-8 PubMed
Expert Rev Vaccines. 2008 Feb;7(1):83-95 PubMed
Vaccine. 2005 Mar 18;23(17-18):2304-10 PubMed
Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):883-5 PubMed
J Chemother. 2007 Jun;19(3):256-62 PubMed
Vaccine. 2010 May 21;28(23):3920-8 PubMed
Vaccine. 2009 Jun 12;27(29):3802-10 PubMed
Clin Microbiol Infect. 2002 Oct;8(10):623-33 PubMed
Orv Hetil. 2009 May 17;150(20):935-41 PubMed
PLoS Med. 2010 Oct 05;7(10): PubMed
Bratisl Lek Listy. 2010;111(7):404-9 PubMed
Pol Merkur Lekarski. 2005 Sep;19(111):494-6 PubMed
Euro Surveill. 2009 Mar 26;14(12): PubMed
Lancet. 2009 Sep 12;374(9693):893-902 PubMed
Int J Pediatr Otorhinolaryngol. 2006 May;70(5):915-23 PubMed
J Chemother. 2007 Oct;19(5):519-27 PubMed
Clin Infect Dis. 2001 Sep 15;33(6):757-62 PubMed
Adv Exp Med Biol. 2001;491:453-71 PubMed
Antimicrob Agents Chemother. 1998 Mar;42(3):589-95 PubMed
Eur J Pediatr. 2006 Sep;165(9):654-7 PubMed
Clin Microbiol Infect. 2010 May;16(5):402-10 PubMed
Euro Surveill. 2005 Sep;10(9):174-8 PubMed
Pneumologia. 2007 Jul-Sep;56(3):118-23 PubMed
Acta Microbiol Immunol Hung. 2008 Dec;55(4):395-407 PubMed
Pediatr Infect Dis J. 2000 May;19(5 Suppl):S37-46 PubMed
Curr Opin Pulm Med. 2010 May;16(3):217-25 PubMed
Arch Intern Med. 2004 Nov 8;164(20):2206-16 PubMed
J Clin Microbiol. 1999 Mar;37(3):638-48 PubMed
Antimicrob Agents Chemother. 2007 Jan;51(1):40-7 PubMed
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):897-910 PubMed
Bull World Health Organ. 2008 May;86(5):408-16 PubMed
Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):787-92 PubMed
Euro Surveill. 1999 Apr;4(4):41-44 PubMed
Clin Infect Dis. 2000 Jan;30(1):100-21 PubMed
Lancet. 2006 Mar 4;367(9512):740-8 PubMed
Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):523-8 PubMed
Vaccine. 2008 Dec 23;26 Suppl 7:G16-9 PubMed
Vaccine. 1999 Jul 30;17 Suppl 1:S79-84 PubMed
Indian J Med Res. 2004 May;119 Suppl:168-70 PubMed
Arch Intern Med. 2010 Apr 26;170(8):725-31 PubMed
Wkly Epidemiol Rec. 2007 Mar 23;82(12):93-104 PubMed
BMC Infect Dis. 2010 Apr 08;10:90 PubMed
Epidemiol Infect. 2009 Apr;137(4):562-9 PubMed
Int J Antimicrob Agents. 2004 Aug;24(2):95-104 PubMed
Pediatr Infect Dis J. 2008 Aug;27(8):709-12 PubMed
Lancet Infect Dis. 2008 Dec;8(12):785-95 PubMed
Expert Rev Anti Infect Ther. 2010 Feb;8(2):151-61 PubMed
Bratisl Lek Listy. 2008;109(5):204-9 PubMed
